You Might Also Like
Also By This Author
- Novartis AG. News release: Novartis’ Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients. 2017 Nov 30.
The Foundation is the largest private funding source for rheumatology research and training in the U.S.
Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.